Could a new drug sharpen the minds of people with schizophrenia?
NCT ID NCT07084831
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a new medicine, Xanomeline/Trospium (also called KarXT), can improve thinking and memory in adults with schizophrenia. Unlike standard antipsychotics, this drug targets a different brain system and may help with cognitive symptoms. Researchers will follow 171 participants for up to a year, measuring changes in cognition, symptoms, and daily life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Xanomeline/Trospium (also known as KarXT/Cobenfy)
What this could lead to
If it works, this could show that Xanomeline/Trospium improves thinking and memory in people with schizophrenia, potentially leading to better daily functioning and quality of life.
What could go wrong
This is an early-phase, open-label study with no placebo group, so results may be less reliable. Cognitive improvements are not guaranteed, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COGNITIVE IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AOU Città della Salute e della Scienza di Torino
Torino, 10126, Italy
Contact Email: •••••@•••••
-
Central Institute of Mental Health
Mannheim, 68159, Germany
Contact Email: •••••@•••••
-
Hospital Clínic de Barcelona
Barcelona, 08036, Spain
Contact Email: •••••@•••••
-
Hospital Universitario La Paz
Madrid, 28046, Spain
Contact Email: •••••@•••••
-
Hospital Universitario Virgen del Rocío
Seville, 41013, Spain
Contact Email: •••••@•••••
-
Ludwig Maximilian University
München, 80336, Germany
Contact Email: •••••@•••••
-
Medical University Innsbruck
Innsbruck, 6020, Austria
Contact Email: •••••@•••••
-
National Institute of Mental Health
Klecany, 250 67, Czechia
Contact Email: •••••@•••••
-
Psykiatrisk Center Glostrup
Glostrup Municipality, 2600, Denmark
Contact Email: •••••@•••••
-
Semmelweis University
Budapest, 1083, Hungary
Contact Email: •••••@•••••
-
Sheba Medical Center
Ramat Gan, Israel
Contact Email: •••••@•••••
-
UPC KU Leuven
Leuven, 3070, Belgium
Contact Email: •••••@•••••
-
University Hospital Cologne
Cologne, 50937, Germany
Contact Email: •••••@•••••
-
University Medical Center Groningen
Groningen, Netherlands
Contact Email: •••••@•••••
-
University of Augsburg
Augsburg, 86156, Germany
Contact Email: •••••@•••••
-
University of Campania Luigi Vanvitelli
Naples, 80138, Italy
Contact Email: •••••@•••••